Kilitch Drugs (India)NSE:KILITCH -4.34%86 Days Payable is 164.60 as of Mar. 2026, which is 11% above its 10-year median of 148.63. GuruFocus rates NSE:KILITCH with a GF Score™ of 86/100 and a GF Value™ of ₹230.39 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 79.43% on this metric.
The historical rank and industry rank for Kilitch Drugs (India)'s Days Payable or its related term are showing as below:
NSE:KILITCH'
s Days Payable Range Over the Past 10 Years
Min: 45.08 Med: 148.63 Max: 290.87
Current: 168.35
During the past 13 years, Kilitch Drugs (India)'s highest Days Payable was 290.87. The lowest was 45.08. And the median was 148.63.
NSE:KILITCH's Days Payable is ranked better than 79.43% of 919
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs NSE:KILITCH: 168.35
Kilitch Drugs (India) Days Payable Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Kilitch Drugs (India)'s Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a Days Payable of 164.60 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kilitch Drugs (India) and its competitors. This is 11% above median its historical median of 148.63. Over the past decade, Kilitch Drugs (India)'s Days Payable has ranged from 45.08 to 290.87. According to the industry distribution chart, Kilitch Drugs (India) ranks #189 out of 919 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Kilitch Drugs (India)'s Days Payable too high?
Kilitch Drugs (India)'s current Days Payable of 164.60 is 11% above median its 10-year median of 148.63. Over the past 10 years, this metric has ranged from a low of 45.08 to a high of 290.87. The Drug Manufacturers industry median Days Payable is 90.69. Kilitch Drugs (India)'s value of 164.60 is 81.5% above this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #189 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kilitch Drugs (India) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #189 out of 919 companies for Days Payable. This places Kilitch Drugs (India) in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Kilitch Drugs (India)'s value of 164.60 is 81.5% above this benchmark. Historically, Kilitch Drugs (India)'s own Days Payable has ranged from 45.08 to 290.87 over the past decade. While the company's 10-year median is 148.63 vs. the industry median of 90.69, Kilitch Drugs (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current Days Payable of 164.60 is 81.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current Days Payable is 164.60, which is 11% above median its own 10-year median of 148.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹230.39, compared to a current price of ₹188.45 — trading 18.2% below its estimated fair value. The current Days Payable is 164.60, which is 11% above median its 10-year median of 148.63 and 81.5% above the Drug Manufacturers industry median of 90.69. Kilitch Drugs (India)'s overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Days Payable is 164.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹188.45 is trading 18.2% below its estimated GF Value™ of ₹230.39.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Days Payable: 164.60 (11% above median its 10-year median of 148.63)
GF Value™: ₹230.39 vs. price of ₹188.45 (18.2% below fair value)
Industry Position: 81.5% above the Drug Manufacturers median (#189 of 919)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
86GF Score
Get the complete analysis for NSE:KILITCH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
